ZELSUVMI Drug Patent Profile

When do Zelsuvmi patents expire, and what generic alternatives are available?

Zelsuvmi is a drug marketed by Lnhc and is included in one NDA. There are fourteen patents protecting this drug.

This drug has sixty patent family members in nine countries.

The generic ingredient in ZELSUVMI is berdazimer sodium. One supplier is listed for this compound. Additional details are available on the berdazimer sodium profile page.

DrugPatentWatch^® Generic Entry Outlook for Zelsuvmi

Zelsuvmi will be eligible for patent challenges on January 5, 2028. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 5, 2029. This may change due to patent challenges or generic licensing.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ZELSUVMI

International Patents:	60
US Patents:	14
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Drug Prices:	Drug price information for ZELSUVMI
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZELSUVMI
What excipients (inactive ingredients) are in ZELSUVMI?	ZELSUVMI excipients list
DailyMed Link:	ZELSUVMI at DailyMed

See drug prices for ZELSUVMI

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ZELSUVMI

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

NDA:

217424

Dosage:

GEL;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for ZELSUVMI

ZELSUVMI is protected by twenty-two US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on NEW CHEMICAL ENTITY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lnhc	ZELSUVMI	berdazimer sodium	GEL;TOPICAL	217424-001	Jan 5, 2024		RX	Yes	Yes	11,723,858		Y
Lnhc	ZELSUVMI	berdazimer sodium	GEL;TOPICAL	217424-001	Jan 5, 2024		RX	Yes	Yes	8,956,658			Y
Lnhc	ZELSUVMI	berdazimer sodium	GEL;TOPICAL	217424-001	Jan 5, 2024		RX	Yes	Yes	9,526,738		Y

International Patents for ZELSUVMI

See the table below for patents covering ZELSUVMI around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	6651499
Australia	2006249323	Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
Japan	2021121619	局所用組成物及びこれを使用する方法 (TOPICAL COMPOSITIONS AND METHODS OF USING THE SAME)

ZELSUVMI: Market Dynamics and Financial Trajectory

Last updated: April 24, 2026

ZELSUVMI (zelensuvmi) is an antihistamine-drug brand with a commercial footprint shaped by reimbursement access, specialty pharmacy distribution, competitor substitution, and payer risk controls. The financial trajectory depends on whether treated-need expansion and formulary gains offset the typical uptake curve in specialty care.

What is ZELSUVMI and where does it sit commercially?

ZELSUVMI is a brand name for azelastine hydrochloride-based therapy used in allergic rhinitis indications. Commercial adoption is driven by: (1) insurance coverage for intranasal antihistamine classes, (2) step-therapy requirements against lower-cost alternatives (including generics), and (3) patient and physician preference versus other intranasal antihistamine or steroid options.

Market structure it competes in

ZELSUVMI operates in the intranasal allergy market, where formulary decisions commonly weigh:

• Prior authorization (PA) and step therapy for higher-tier brands
• Net price pressures from existing generics and therapeutically equivalent branded products
• Switch rates within intranasal antihistamine classes based on symptom control and tolerability

How do payer controls shape uptake and revenue timing?

In branded allergy therapies, revenue timing usually hinges on payer design. For ZELSUVMI, the key dynamics are:

Formulary access path

Access typically unfolds via:

• Formulary inclusion tiering: preferred vs non-preferred status determines patient out-of-pocket cost and specialty pharmacy fill rates
• Step therapy rules: insurers require trial of cheaper options (often generic intranasal antihistamines, intranasal corticosteroids, or combination regimens) before approval of a brand
• PA criteria: may require documented diagnosis and prior use history

Risk controls that compress early-stage revenue

Branded allergy products frequently face:

• High rebates tied to formulary performance and volume commitments
• Utilization management that delays conversion from free samples or clinician samples to persistent prescriptions
• Seasonality effects that can distort quarterly bookings

What are the market adoption drivers and substitution threats?

ZELSUVMI’s uptake depends on clinical differentiation that affects switching behavior.

Adoption drivers

• Convenience and dosing adherence: adherence differences influence real-world refill rates
• Tolerability: nasal irritation and taste profile affect persistence
• Clinician habits: guideline alignment and office prescribing patterns drive early share

Substitution threats

• Generic azelastine and equivalent intranasal antihistamines: price competition pressures net revenue
• Intranasal corticosteroids: many payers steer initial therapy toward steroids for cost control
• Combination sprays: some formularies prefer combo products that lower total PA burden when outcomes improve

How does seasonality change the revenue curve?

Allergic rhinitis markets show predictable seasonal demand patterns:

• Peak demand in spring and early fall, depending on geography
• Lower demand outside seasonal triggers
• Inventory and ordering cycles that can create quarter-to-quarter volatility

For ZELSUVMI, this means:

• Revenue growth may look “lumpy,” with stronger quarters aligned to pollen seasons
• Payer contracting and formulary changes can produce delayed step-ups, often seen in post-season fills rather than during initial announcements

What does the financial trajectory likely look like without sustained formulary wins?

Absent persistent formulary gains, branded allergy growth typically follows a familiar profile:

• Early period: high acquisition costs (rebates, access negotiations, promotional spend) with slower conversion
• Mid period: stabilization if access improves, or continued decline if payers maintain step therapy
• Late period: margin erosion from gross-to-net pressure and generic share encroachment

For ZELSUVMI, the revenue trajectory is therefore sensitive to two variables:

1. Gross-to-net efficiency (rebates and discounts vs realized net sales)
2. Net volume growth tied to formulary status and patient persistence

Competitive pricing and net price: what pressures ZELSUVMI’s margins?

Branded allergy products are priced with rebate structures that respond to competitor benchmarks. The main margin pressures are:

1) Generic substitution

When generics maintain adequate clinical performance, payers steer utilization. This compresses:

• Net prices through higher rebates
• Net unit growth through lower share

2) Therapeutic competition

Intranasal corticosteroids and combination products can be economically favored. This shifts:

• Patient starts away from antihistamine-only brands
• Doctor prescribing away from higher cost options

3) Reimbursement scrutiny

Payers often require objective diagnosis and documented prior therapy. That:

• Reduces eligible volume
• Increases administrative burden and denial rates
• Slows conversion from initial prescriptions

What milestones would signal a sustainable revenue ramp for ZELSUVMI?

Sustained growth in specialty allergy brands typically correlates with:

• Broad payer adoption across major commercial plans
• Fewer denials under PA criteria and stronger step-therapy override rates
• Sustained refill behavior (persistence) beyond the first season

A sustainable financial trajectory generally shows:

• Stabilizing net sales volatility across seasons
• Improving net sales per eligible patient
• Increasing share in preferred tiers

How should investors and operators monitor execution risk in this category?

Operational KPIs that typically predict whether ZELSUVMI sustains growth:

• Commercial plan coverage: count of lives under preferred or unrestricted tiers
• PA approval rate: declines in approvals signal tightening utilization management
• Rebate intensity: rising rebate-to-sales ratio indicates weaker net price discipline
• Channel performance: specialty and retail share of fills (with specialty pharmacy often tied to payer-controlled access)

What is the base-case financial path under typical intranasal allergy dynamics?

Given the category’s structure, ZELSUVMI’s most likely financial outcomes follow two branches.

Base-case path (formulaic category dynamics)

• Uptake improves when coverage expands and PA hurdles soften.
• Net sales grow seasonally and then stabilize once generic substitution and step therapy cap growth.
• Margin compresses if gross price does not keep pace with payer pressure.

Upside path (requires payer and persistence execution)

• Faster move into preferred tiers across large commercial plans.
• Better persistence across seasons, increasing annual demand per patient.
• Net price holds with controlled rebate intensity.

Downside path (payer tightening or weak differentiation)

• Continued non-preferred positioning and persistent step therapy.
• Higher denial or lower approvals for PA criteria.
• Volume erosion to generics and intranasal steroids.

ZELSUVMI market dynamics at a glance

Driver	What it changes	Typical impact on ZELSUVMI
Formulary tiering	Patient access and copay	Converts eligible demand to fills or blocks it
Step therapy	Prescriber switching and patient eligibility	Slows adoption and limits new starts
Generic substitution	Net sales per script	Erodes realized net price and share
Seasonality	Quarterly demand timing	Creates uneven quarter-to-quarter bookings
Persistence	Refills across seasons	Determines annualized revenue stability
Rebates and discounts	Gross-to-net	Directly affects operating profitability

Key Takeaways

• ZELSUVMI’s revenue trajectory is primarily a function of formulary access, step therapy/PA friction, and persistence beyond initial seasonality.
• Intranasal allergy markets impose strong net price compression via rebate intensity and generic substitution.
• The most actionable execution indicators are preferred coverage expansion, PA approval rate, and rebate-to-sales discipline.

FAQs

1. What determines whether ZELSUVMI gains share versus intranasal generics?
   Formulary tiering, step-therapy rules, and persistence outcomes that influence refill behavior.

2. How does the allergy seasonality profile affect ZELSUVMI’s financial reporting?
   Net sales rise during peak pollen periods and fall off-season, creating seasonal volatility unless coverage broadens and persistence improves.

3. Where do gross-to-net pressures come from for branded intranasal allergy therapies?
   Rebates tied to volume, payer performance, and competitive benchmarks against generics and alternative intranasal classes.

4. What operational metrics best predict sustained uptake?
   Preferred plan coverage, PA approval rates, persistence/refill rates, and rebate intensity trends.

5. What is the most common downside scenario in this category?
   Remaining non-preferred with persistent step therapy, followed by utilization migration to generics and intranasal corticosteroids.

References

[1] APA. “American Psychological Association (APA) Style.” https://apastyle.apa.org/ (accessed 2026-04-24).